PURE Creates Market Development Team Focused on Direct Food Contact Application

New SDC Application Merits Dedicated Senior Marketing Executive

Marketwired

SAN DIEGO, CA--(Marketwired - Jun 6, 2014) -  PURE Bioscience, Inc. (OTCQB: PURE), creator of the patented silver dihydrogen citrate (SDC) antimicrobial, today announced that Bridget Tinsley joined PURE in the newly created position of Vice President Market Development. Tinsley will be responsible for both expanding the market for SDC as a food contact surface disinfectant and sanitizer and leading the future commercial applications of SDC as a food safety aid in the processing of poultry, meat and produce. Tinsley has nearly fifteen years of food industry and food safety experience with diverse expertise across global food programs, territory sales, account management, and laboratory research and business development.

Prior to joining PURE, Tinsley served as Senior Food Safety & Regulatory Specialist with Thermo Fisher Scientific. She previously served as the Manager of Global Food Programs for Underwriters Laboratories, LLC, where she was responsible for numerous global initiatives, including validation/verification services, and business development. Prior to joining UL, Tinsley conducted extensive research on antimicrobial solutions and delivery systems. She was the project leader for the approval and adoption of the antimicrobial treatment Sanova® in the meat, poultry and produce industry. Tinsley was instrumental in the development of a commercial pathogen reduction solution and helped take a startup company to the point where it was acquired by an industry leader. Tinsley is a Director and Secretary of STOP Foodborne Illness, a public health and food safety organization.

Tinsley earned her Masters of Science in Food Microbiology from Kansas State University.

"With Bridget's experience, we believe that she is the right leader at the right time for PURE. We are confident in her ability to bring our new SDC Direct Food Contact antimicrobial successfully to market, and to expand our market penetration of SDC as a food contact surface disinfectant," said Hank R. Lambert, PURE's CEO.

Tinsley stated, "SDC will certainly be one of the most important advances in food safety for food processing/manufacturing in many decades. I feel privileged to lead the effort to bring this important direct food contact antimicrobial to market. I believe SDC has the capability of eliminating pathogens as a threat in the processing of poultry, meats and produce. Everyone in the supply chain, from farmers to processors to consumers, should welcome this game-changing advance."

About PURE Bioscience, Inc.
PURE Bioscience, Inc. is focused on developing and commercializing our proprietary antimicrobial products that provide solutions to the health and environmental challenges of pathogen and hygienic control. Our technology platform is based on patented stabilized ionic silver, and our initial products contain silver dihydrogen citrate, or SDC. SDC is a broad-spectrum, non-toxic antimicrobial agent, which offers 24-hour residual protection and formulates well with other compounds. As a platform technology, SDC is distinguished from existing products in the marketplace because of its superior efficacy, reduced toxicity and the inability of bacteria to form a resistance to it. PURE is headquartered in El Cajon, California (San Diego metropolitan area). Additional information on PURE is available at www.purebio.com.

Forward-looking Statements
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements inherently involve risks and uncertainties that could cause our actual results to differ materially from the forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, the Company's cash position and liquidity requirements, the Company's failure to implement or otherwise achieve the benefits of its proposed business initiatives and plans, acceptance of the Company's current and future products and services in the marketplace, the ability of the Company to develop effective new products and receive regulatory approvals of such products, competitive factors, dependence upon third-party vendors, and other risks detailed in the Company's periodic report filings with the Securities and Exchange Commission, including our annual report on Form 10-K filed October 24, 2013. You should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release.

Contact:

Tom Hemingway
Redwood Investment Group
714-978-4425
Email Contact

Terri MacInnis
VP of IR
Bibicoff + MacInnis, Inc.
818-379-8500
Email Contact

Company
Peter C. Wulff
CFO & COO
PURE Bioscience, Inc.
619-596-8600 ext.111
Email Contact
View Comments (0)